Evidence map›Paper›PMID 39716909›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Biomimetic Vascularized iPSC-Hepatocyte Spheroids for Liver Regeneration.

Jinglin Wang, Danqing Huang, Haozhen Ren, Yuanjin Zhao

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Emerging nanomedicine for liver diseases treatment.Journal of nanobiotechnology · 2025
    Review
  8. Review
  9. Biomimetic Vascularized iPSC-Hepatocyte Spheroids for Liver Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jinglin WangDivision of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, China.
Danqing HuangDivision of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, China.
Haozhen RenDivision of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, China.
Yuanjin ZhaoDivision of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, China.ORCID https://orcid.org/0000-0001-9242-4000

Funding

Clinical Trials from Nanjing Drum Tower Hospital 2022-LCYJ-ZD-01;2022-LCYJ-PY-35;2021-LCYJ-PY-46Guangdong Basic and Applied Basic Research Foundation 2021B1515120054Shenzhen Fundamental Research Program JCYJ20190813152616459;JCYJ20210324133214038the Jiangsu Provincial Science and Technology Special Fund for Outstanding Young Scholars BK20230051the Nanjing Health Science and Technology Development Project for Distinguished Young Scholars JQX22003The National Key Research and Development Program of China 2022YFA1105300The National Natural Science Foundation of China 82100664;82270646;T2225003
6 · The paper itself

Abstract

Human induced pluripotent stem cell derived hepatocytes (hiPSC-heps) hold promising value for acute liver failure (ALF) treatment, while their therapeutic efficacy is usually limited by low cell bioactivity and untargeted in vivo accumulation. Here, inspired by vascularity supporting cellular architectures in the tissues and organs, a novel vascularized hiPSC-heps spheroid based on microfluidic microcapsules is presented for liver repair via orthotopic transplantation. The microcapsules are comprised of aqueous cores that facilitate hiPSC-hep aggregating into spheroids, and hybrid hydrogel shells of sodium alginate and hyaluronic acid methacryloyl (HAMA). By selectively degrading the alginate, the microcapsules are imparted with porous HAMA shells, which not only allowed human umbilical vein endothelial cells (HUVECs) to attach and form vascularized networks, but also facilitated communication between HUVECs and hiPSC-heps. The specific spatial distributions of these cells in the vascularized hiPSC-hep spheroids can provide nutrition support, promote the hepatic functions, and avoid immune cell attacks. Based on these features, it is illustrated that the vascularized hiPSC-hep spheroids can repair the acute failing liver more effectively, indicating their practical values in clinical liver repair.

Indexed as

BiomimeticsHepatocytesInduced Pluripotent Stem CellsLiver RegenerationSpheroids, CellularAlginatesAnimalsHumansHuman Umbilical Vein Endothelial CellsLiverMiceAlginatesBiomimeticliver regenerationmicrocapsulemicrofluidicvascularized spheroids

Identifiers

PMID39716909
PMCPMC11809326

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.